The role of factor XIII in surgery for advanced stage of epithelial ovarian cancer.
Complications
Factor XIII
Ovarian cancer
Surgery
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
05
08
2021
accepted:
21
10
2021
pubmed:
2
11
2021
medline:
20
4
2022
entrez:
1
11
2021
Statut:
ppublish
Résumé
Hereditary factor (F) XIII-deficiency is a known risk factor for postoperative complications, but data of acquired FXIII-deficiency in malignancies are limited. Therefore, we evaluated the role of acquired FXIII-deficiency in surgery for advanced epithelial ovarian cancer (EOC). We performed a retrospective analysis of patients with known serum FXIII status and treatment between 2011 and 2018 at our center. We defined cohorts according to FXIII with values > 75% as normal (group A), 55-75% as reduced (group B) and < 55% as low (group C). Complications were classified according to the Clavien-Dindo Classification, class III-V complications were defined as severe. 347 patients with EOC were identified. 180 patients (51.2%) were in group A, 82 patients (23.6%) in group B, and 85 patients (24.4%) in group C. Lower levels of FXIII were associated with higher amount of ascites, FIGO IV, high grade serous histology, low albumin, and higher CA-125 levels. Regarding intraoperative variables, low FXIII was associated with longer duration of surgery, higher blood loss, higher surgical complexity score/number of bowel anastomosis and a higher probability for macroscopic residual disease. The risk of severe complications in group A was 12.2%, 24.4% in group B, and 31.8% in group C. In a multivariate model, low FXIII (OR 2.8), > 1 bowel anastomosis (OR 2.7), age-adjusted Charlson comorbidity index ≥ 4 (OR 3.6) and a longer duration of surgery (> 285 min.) were significant predictive factors for severe complications. FXIII is associated with tumor and treatment burden. A low level of FXIII is associated with postoperative complications. The knowledge about the presurgical serum FXIII-level might be helpful to plan the treatment strategy.
Identifiants
pubmed: 34724570
doi: 10.1007/s00404-021-06308-z
pii: 10.1007/s00404-021-06308-z
doi:
Substances chimiques
F8 protein, human
839MOZ74GK
Factor VIII
9001-27-8
Factor XIII
9013-56-3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1311-1318Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
S3-Leitlinie (2019) Maligne ovarialtumoren, Ovarialkarzinom, p 79
Nagy JA, Masse E, Herzberg K et al (1995) Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Res 55:369–375
Dvorak HF (1986) Tumors: wounds that do not heal Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650–1659
Wang X, Wang E, Kavanagh J et al (2005) Ovarian cancer, the coagulation pathway and inflammation. J Transl Med 3:25
doi: 10.1186/1479-5876-3-25
Shi DY, Wang SJ (2017) Advances of coagulation factor XIII. Chin Med J 130:219–223
Dufner GS, Marbet GA (2002) Factor XIII in man: a review. Hamostaseologie 22(1):11–19
Andersson C, Kvist P, McEllhiney K et al (2015) Factor XIII transglutaminase supports the resolution of mucosal damage in experimental colitis. PLoS ONE 10:e0128113
doi: 10.1371/journal.pone.0128113
Inbal A, Lubetsky A, Krapp T et al (2005) Impaired wound healing in factor XIII deficient mice. Thromb Haemost 94:432–437
Higaki S, Nakano K, Onaka S et al (2006) Clinical significance of measuring blood coagulation factor XIIIA regularly and continuously in patients with Crohn’s disease. J Gastroenterol Hepatol 21:1407–1411
Palumbo JS, Barney KA, Blevins EA et al (2008) Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J Thromb Haemost 6:812–819
doi: 10.1111/j.1538-7836.2008.02938.x
Muszbek L, Katona É, Kerényi A (2017) Assessment of factor XIII. Methods Mol Biol 1646:277–293
doi: 10.1007/978-1-4939-7196-1_22
Dorgalaleh A, Tabibian S, Shams M et al (2019) A unique factor XIII mutation in southeastern iran with an unexpectedly high prevalence: khash factor XIII. Semin Thromb Hemost 45(1):43–49
doi: 10.1055/s-0038-1676580
Ichinose A (2017) Japanese Collaborative Research Group on AH13. Autoimmune acquired factor XIII deficiency due to anti-factor XIII/13 antibodies: A summary of 93 patients. Blood Rev 31(1):37–45
Pötzsch B, Madlener K (2002) Gerinnungskonsil. Thieme Verlag, Rationelle Diagnostik und Therapie von Gerinnungsstörungen. Stuttgart
doi: 10.1055/b-002-19466
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213
doi: 10.1097/01.sla.0000133083.54934.ae
Lee SH, Suh IB, Lee EJ et al (2013) Relationships of coagulation factor XIII activity with cell-type and stage of non-small cell lung cancer. Yonsei Med J 54(6):1394–1399
doi: 10.3349/ymj.2013.54.6.1394
Kappelmayer J, Simon A, Katona E et al (2005) Coagulation factor XIII-A. A flow cytometric intracellular marker in the classification of acute myeloid leukemias. Thromb Haemost 94(2):454–9.
Harter P, Sehouli J, Lorusso D et al (2019) A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med 380:822–832
doi: 10.1056/NEJMoa1808424
Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386(9990):249–257
doi: 10.1016/S0140-6736(14)62223-6
Kahl A, du Bois A, Harter P et al (2017) Prognostic Value of the Age-Adjusted Charlson Comorbidity Index (ACCI) on Short- and Long-Term Outcome in Patients with Advanced Primary Epithelial Ovarian Cancer. Ann Surg Oncol 24(12):3692–3699
doi: 10.1245/s10434-017-6079-9
Obermair A, Hagenauer S, Tamandl D et al (2001) Safety and efficacy of low anterior en bloc resection as part of cytoreductive surgery for patients with ovarian cancer. Gynecol Oncol 83:115–120
doi: 10.1006/gyno.2001.6353
Ataseven B, du Bois A, Reinthaller A et al (2015) Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery. Gynecol Oncol 138(3):560–565
doi: 10.1016/j.ygyno.2015.07.005
Moore KN, Reid NS, Fong DN et al (2008) Ovarian cancer in octogenarian: does the paradigm of cytoreductive surgery and chemotherapy still apply? Gynecol Oncol 110(2):133–139
doi: 10.1016/j.ygyno.2008.03.008
Aletti GD, Eisenhauer EL, Santillan A et al (2011) Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol 120(1):23–28
doi: 10.1016/j.ygyno.2010.09.010
Nieuwenhuyzen-de Boer GM, Gerestein CG, Eijkemans MJ, Burger CW, Kooi GS (2016) Nomogram for 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer. Eur J Gynaecol Oncol 37(1):63–68
Grimm C, Harter P, Alesina PF et al (2017) The impact of type and number of bowel resections on anastomotic leakage risk in advanced ovarian cancer surgery. Gynecol Oncol 146(3):498–503
doi: 10.1016/j.ygyno.2017.06.007
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248–1259
doi: 10.1200/JCO.2002.20.5.1248
Du Bois A, Reuss A, Pujade-Lauraine E et al (2009) The role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer. Cancer 15:1234–1244
doi: 10.1002/cncr.24149